Company intelligence / Profile preview

Alto Neuroscience

Mountain View, California, United Statesaltoneuroscience.com ↗

Ownership: Public · ANRO
Development stage: Other

Overview

Alto Neuroscience has reported positive interim results from a double-blind Phase IIb trial of ALTO‑300 for major depressive disorder using an EEG biomarker to identify likely responders. The company’s pipeline includes several clinical-stage candidates for depression and schizophrenia. A new Phase II trial of ALTO‑203 began in April 2024 targeting MDD with anhedonia; topline data are expected in the first half of next year. The company leverages its proprietary Precision Psychiatry Platform to match patients with therapies based on brain biomarkers.

Therapeutic areas: Psychiatry
Modalities: Small molecules
Industry: Biotech

Drug pipeline

10 assets

alto-203

9 more assets in the full pipeline.

Financials

Market cap: $858.2M
Total revenue: $0
Enterprise value: $621.5M

Beyond the preview

Go deeper on Alto Neuroscience.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Alto Neuroscience.